Background. Group B Streptococcus (GBS) disease is the leading cause of neonatal bacterial meningitis despite women receiving an intravenous antibiotic prophylaxis during labor. We aimed to describe GBS meningitis in children <1 year old in France.
Group B Streptococcus (GBS) disease is now the third most common cause of bacterial meningitis in children, after Streptococcus pneumoniae and Neisseria meningitidis infection, and the leading cause of neonatal bacterial meningitis [1, 2] . The incidence of invasive GBS disease in newborn and infants 0-89 days old greatly varies worldwide, from 0.57 per 1000 live births in Europe to 1.21 per 1000 in Africa [3] . Specific data on GBS meningitis (the more severe cause of GBS diseases) are relatively rare because they are usually included with data on overall invasive GBS disease.
Human GBS isolates express a capsular polysaccharide (CPS), and isolates can be divided into 10 CPS serotypes (Ia, Ib, II-IX), each antigenically and structurally unique. A recent global review of invasive isolates revealed serotype III as the most frequent (48.9%) in all regions with available data, followed by serotypes Ia (22.9%), V (9.1%), Ib (7.0%), and II (6.2%) [3] . Multilocus sequence typing allows for identifying genetically related GBS isolates on the basis of similarities in 7 conserved housekeeping genes. Five major clonal complexes (CCs) have been identified: CC1, CC12, CC19, CC17, and CC23 [4] . CC17 represents almost 70% of GBS isolates responsible for neonatal meningitis but was detected in <12% of adult disease [5] .
Usually 2 types of neonatal meningitis are described: early-onset disease (EOD) and late-onset disease (LOD). EOD occurs in the first week of life (age 0-6 days) and represents about 30% of GBS disease in children, whereas LOD occurs in newborns and infants aged 7-89 days, is mostly associated with meningitis, and represents about 60% of infant GBS disease [6] . Before the intrapartum antibiotic prophylaxis (IAP) era, maternal intrapartum GBS colonization was the primary risk factor for EOD, and in the absence of IAP, EOD was twice as common as LOD [7] . The risk of delivering infants with EOD was 25-fold greater for pregnant women with than without GBS vaginal colonization [8] .
Since the beginning of the 1990s, IAP during labor has been initiated in some high-income countries [7, 9] . In 2001, the French health authority recommended antenatal vaginal cultures for women between 34 and 38 weeks' gestational age (GA) to identify women who needed to receive IAP during labor, and this move has decreased the incidence of neonatal GBS EOD in France (0.69/1000 to 0.20/1000 live births from 1997 to 2006) [10] . This decrease was also reported in other countries where IAP was implemented [3] . However, quickly, LOD cases were found not to be prevented by IAP. GBS can also be responsible for diseases in young infants >3 months, those with infant disease (ID). ID cases are less frequent and poorly described in the literature but may be responsible for meningitis, pneumonitis, sepsis, urinary tract infection, and arthritis [11, 12] .
Preterm birth is a risk factor for GBS EOD [6] ; previous studies showed that preterm birth could be an important risk factor for LOD and even more so for ID [11] . Candidate vaccines against GBS are under development, and studies of GBS immunization of pregnant women to protect neonates against EOD and LOD are ongoing [13] .
In 2001, the Pediatric Infectious Disease Group (GPIP) and ACTIV (Association Clinique et Thérapeutique Infantile du Val de Marne) of the French Pediatric Society established a national active surveillance of bacterial meningitis [1] . Here we report data on GBS meningitis in newborns and infants over a 14-year period to follow the trends of EOD, LOD, and ID.
MATERIALS AND METHODS

Population
From January 2001 to December 2014, 259 pediatric wards working with 168 microbiology laboratories throughout France prospectively enrolled all reported cases of GBS meningitis in children from 0 to 365 days old. For this hospital-based active surveillance, 3 times a year, a clinical investigator in each participating ward was contacted for information on new cases or to confirm the lack of such cases. After patient discharge, a standardized data form was completed by a designated clinical investigator and was sent by email or post to ACTIV. The birth weight was studied according to standard growth curves developed by the Association of Users of Computerized Data in Pediatrics, Obstetrics, and Gynecology (AUDIPOG). The cases were characterized as small for gestational age (<10th percentile) or appropriate for GA. Four groups of infants were defined: EOD (0-6 days old), LOD1 (7-26 days old), LOD2 (27-89 days old), and ID (3 months-1 year old). The cases were classified as term (≥37 weeks) or preterm (<37 weeks) at birth. The detection of GBS in cerebrospinal fluid (CSF) by positive culture (± pleocytosis ≥10 cells/μL) was used as diagnostic criteria for GBS meningitis. For cases with negative CSF culture, the diagnostic criteria for GBS meningitis was a positive antigen test result and/or polymerase chain reaction (PCR) result or a positive blood culture with CSF pleiocytosis.The questionnaire collected data on white blood cell count, C-reactive protein level, lumbar puncture results (cellularity, neutrophil cell count, glucose and protein levels, culture), antimicrobial therapy during the current episode, complications (seizures, shock, coma, mechanical ventilation), and death. The data collection was approved by the French National Data Protection Commission (CNIL; number 913006).
Microbiology
GBS strains were identified by standard methods in the microbiology laboratory of each hospital. The strains were sent voluntarily to the French National Reference Center for Streptococci (CNR-Strep) for confirmation and molecular typing. Data from CNR-Strep and ACTIV were linked to match the strains and clinical data.
Statistical Analysis
Stata SE version 13.1 software (StataCorp, College Station, Texas) was used for analysis. Data were analyzed by EOD, LOD1, LOD2, and ID groups, GA, and study year. Quantitative data were analyzed by 1-way analysis of variance and categorical data by χ 2 test or Fisher exact test. Trend tests involved the Cuzick test. Statistical significance was set at 2-sided P < .05, and 95% confidence intervals (CIs) were calculated. To estimate the incidence of meningitis, we used a capture-recapture analysis; the completeness of the system was 61% (95% CI, 60%-66%) [14] . The incidence with 95% CI was calculated as number of GBS meningitis cases × completeness of the system / 1000 × total number of live births. To identify risk factors of mortality, multivariable regression analysis was used to estimate odds ratios (ORs) and 95% CIs. All data with P < .25 on univariable analysis were included in the multivariable model: age group, GA, seizures before and during treatment, shock, and coma. Mechanical ventilation as a result of coma was not included in the model. Only data with P < .05 were kept in the final model.
RESULTS
Epidemiologic, Clinical, and Biological Characteristics
From . Abbreviations: CI, confidence interval; EOD, early-onset disease (age 0-6 days); ID, infant disease (age 3 months to 1 year); LOD, late-onset disease (age 7-89 days); LOD1, late-onset disease (age 7-26 days); LOD2, late-onset disease (age 27-89 days).
The number of ID meningitis cases remained stable during the study period. Between 2001 and 2014, the incidence of GBS meningitis per 1000 live births was lowest in 2004 (0.09 [95% CI, .7-.11]) and highest in 2014 (0.14 [95% CI, .11-.17]) for the whole population. From 2001 to 2014, the incidence of EOD meningitis decreased from 0.06 (95% CI, .04-.08) to 0.02 (95% CI, .01-0.04) (P = .001), whereas that of total LOD meningitis increased from 0.06 (95% CI, .05-.08) to 0.1 (95% CI, .08-.13) (P = .003; Figure 2B ). Clinical characteristics of infants by disease age groups are shown in Table 1 . The frequency of prematurity was significantly higher with ID than EOD, LOD1, and LOD2: 55.7% vs 9.7%, 14.3%, and 28.4%, respectively (P < .001; Figure 3 ). The groups did not differ in breastfeeding (P = .9; 55.7% among 510/848 cases with available data), and the number of women who breastfed remained stable during the study (P = .8). Sixteen patients featured 18 underlying conditions: EOD accounted for 18.8%, LOD for 75%, and ID for 6.2%. Maternal human immunodeficiency virus seropositivity (n = 6) was the most frequent underlying conditions, followed by immunodeficiency (n = 4), meningeal break (n = 3), recurrent meningitis (n = 3), cardiopathy (n = 1), and valve (n = 1).
Information on antenatal GBS maternal screening was available for 388 cases (45.7%) and was positive for 120 (30.9%), with no significant difference among the 4 groups ( Table 1 ).
The proportion of women who had received IAP (Table 1) 
The Supplementary Data 1 shows CSF and blood features of infants according to age groups.
Microbiological Characteristics
CSF Gram staining and culture were positive in 75.4% (n = 625) and 88.6% (n = 751) of the 848 GBS cases, respectively. With negative CSF culture (n = 97), microbiological diagnosis was based on at least 1 of the following methods: positive blood culture with CSF pleocytosis (n = 42 [5.0%]), CSF antigen detection (n = 36 [4.6%]), and positive CSF PCR result (n = 19 [2.2%]). The proportions of these tests performed during the study period did not change significantly.
Among the 372 available GBS serotypes (43.9%), the distribution did not differ among the 4 groups, and serotype III accounted for 83.9% of cases (see Supplementary Data 2), with no significant difference among the 4 groups or by GA. Among 243 cases analyzed, CC17 was found only among GBS serotype III. The prevalence of CC17 did not differ among the 4 groups or by GA (see Supplementary Data 3).
Treatment and Outcomes
All children received β-lactam antibiotics (cefotaxime or aminopenicillins), with aminoglycosides in 88% of cases. Intravenous steroids were used in <10% of the 4 groups. Abbreviations: AGA, appropriate gestational age; EOD, early-onset disease (age 0-6 days); GA, gestational age; GBS, group B Streptococcus; IAP, intrapartum antibioprophylaxis; ID, infant disease (age 3 months to 1 year); LOD1, late-onset disease (age 7-26 days); LOD2, late-onset disease (age 27-89 days); SGA, small for gestational age; SD, standard deviation.
Case fatality was 11.4%, with no difference among the 4 groups. Table 2 shows the risk factors of death for GBS meningitis. The mean time from hospital admission to death was 10.4 days, significantly lower for ID meningitis (7 ± 2.7 days) than other groups. On multivariable analysis, coma and shock were the 2 significant risk factors for mortality (ORs, 14.9 [95% CI, 7.9-27.8] and 5.8 [95% CI, 3.0-11.3], respectively).
DISCUSSION
To our knowledge, this study is the largest published series of neonatal and infant GBS meningitis, with 848 cases during the 14-year study period. Our study shows a significant decrease in the incidence of EOD GBS meningitis (probably due to the use of IAP) as well as an increase in that of LOD meningitis. However, a few cases of EOD continue to be reported despite antibiotics recommendations for pregnant women in 2001 [10] . Previous studies of EOD GBS during the era of universal and widespread IAP suggested that the remaining cases are due to problems encountered in patient healthcare (GBS antenatal vaginal screening not performed or giving false-negative results, IAP could not be administered properly, or risk of recolonization between sample collection and infant delivery) [15, 16] . In our study, 37% of EOD meningitis cases had data on maternal colonization status, and only 25% of cases with positive antenatal screening results had received IAP.
Because LOD and ID are not preventable by IAP, their distribution should remain stable over the years: Our data showed an increase in the number of LOD meningitis cases and stability in the number of ID meningitis cases. From 2001 to 2014, the number of centers in our study has remained stable and the method of diagnosis was the same across all centers, with no changes in use of PCR or other methods of diagnosis [17] .
Recent data from the Netherlands showed, from 1987 to 2011, an increased incidence of invasive GBS disease (EOD from 0.11/1000 to 0.19/1000 live births, P < .001; and LOD from 0.03/1000 to 0.13/1000, P = .04) [18] . Several factors could contribute to the increased incidence of LOD. In France from 1995 to 2010, the prevalence of preterm births increased from 5.9% to 7.4%; indeed, in our study, among children with GBS meningitis, preterm infants accounted for 14.9% in 2001 to 26.6% in 2014 [19] . We found prematurity accounting for 55.7%, 28.4%, and 14.3% of ID, LOD2, and LOD1 meningitis cases, respectively. Recently, Miller et al showed preterm and early preterm birth, low birth weight, and low birth length to be associated with persistently increased rate of disease [20] . Figure 3 . Distribution of disease age groups by gestational age. Abbreviations: EOD, early-onset disease (age 0-6 days); ID, infant disease (age 3 months to 1 year); LOD1, late-onset disease (age 7-26 days); LOD2, late-onset disease (age 27-89 days). The case-fatality rate of 11.4% was comparable to that reported in other recent studies [2, 21] . We also identified other recognized risk factors for mortality, such as prematurity and seizures. Unlike previous studies, we did not find birth weight to be a risk factor for mortality [6, 21, 22] . Previous studies found seizures and CSF protein level >5 g/L to be associated with poor outcomes [21, 23] .
The emergence of new and more virulent GBS types could be another explanation for our findings [24] . Bekker et al showed an increase in CC17 prevalence in 2014 after recommendations for IAP in the Netherlands [18] . In our study, the serotype distribution of GBS isolates was similar to that described worldwide [3, 6, 11, 18, 25] . The main GBS serotype was serotype III among the 4 groups and was almost represented completely by CC17. This overrepresentation of CC17 among invasive infant strains highlights that this clone is well adapted to neonate pathogenesis and may possess specific virulence traits that enhance its invasiveness in this population. These characteristics must be accounted for in developing new prevention strategies [26] .
In contrast to the pathophysiology of EOD, that of LOD and ID remains uncertain. Long-term GBS persistence in the neonatal gut (up to 1 year) after colonization at birth has been demonstrated [27] , but the infection also can be a new acquisition. With the current knowledge, the role of breast milk in pathogen transmission to the neonate cannot be definitively established [28] . Some experts believe that the GBS organism initially colonizes the neonate's oropharyngeal mucosa from perinatal sources; during breastfeeding, the mammary ducts become infected and the infant is infected another time during feeding, regardless of mastitis [29] . However, Olver et al described cases of GBS disease in preterm infants fed maternal milk via nasogastric tube alone [30] .
Given the increase in number of LOD cases and the absence of disease prevention by IAP, an alternative is the vaccination of pregnant women. The current leading vaccine candidates are CPS-protein conjugate vaccines [31] [32] [33] . Edwards et al found that 72% of infants born at or near term were infected within the first 6 weeks of life. These data suggest that a GBS vaccine could reduce late-onset GBS meningitis [34] [35] [36] . With the increase and virulence of CC17, CC17-specific antigens should be considered in the design of future vaccines. One of the limitations of the vaccine strategy could be the large proportion of preterm infants who may not be protected. However, recent studies for pertussis vaccine showed that preterm neonates benefit from second-rather than third-trimester pertussis maternal immunization [37] . A similar effect could be expected for GBS vaccines, and this hypothesis deserves to be tested. An additional reason for supporting the GBS vaccine strategy is the potential impact also on EOD that could allow for reducing the use of IAP. In light of the growing resistance to all antibiotic prescriptions, the impact of IAP on the developing intestinal microbiota of the neonate is also a concern [38] .
Our study has several limitations. First, because data collection was derived from discharge summaries, some data are incomplete for some factors playing a role in the incidence of GBS meningitis, such as GBS antenatal screening, IAP, modes of delivery, and bacteriological samples of mothers' milk. Second, the long-term outcome and complications of cases enrolled were not recorded. Finally, data on the serotype and genotype of GBS strains were known for only 43.9% and 27.6% of cases, respectively. Even if our network has been stable since the beginning of the surveillance period, we cannot rule out a more thorough case reporting or that cases could have escaped our surveillance; however, we used the same surveillance network with the same centers for the past 14 years. The high quality of our surveillance system was assessed by the capture-recapture method, and clinical investigators consistently reported a high response over the study period. Moreover, our results do not appear to be explained by changes in clinical practice because the indications for lumbar puncture did not change during the 14-year study period. To support that ascertainment and investigation of cases of meningitis has been relatively constant during the observation period, the incidence of bacterial meningitis with E. coli infection has not changed over the years [39] .
In conclusion, in the era of IAP, we found a decrease in the incidence of early-onset GBS meningitis and, in the same timeframe, unexpectedly, an increase incidence of LOD. These data underline the interest of the development of effective GBS vaccines for pregnant women.
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